Spero Therapeutics to Present Data at IDWeek 2022
October 19, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
October 03, 2022 08:05 ET
|
Spero Therapeutics, Inc.
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical...
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
September 22, 2022 02:00 ET
|
Spero Therapeutics, Inc.
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential...
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
September 15, 2022 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal...
Spero Therapeutics to Present at Upcoming Investor Conference
September 07, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
September 06, 2022 08:05 ET
|
Spero Therapeutics, Inc.
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients...
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
August 10, 2022 16:05 ET
|
Spero Therapeutics, Inc.
Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen...
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 09, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022...
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
June 27, 2022 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
May 16, 2022 16:05 ET
|
Spero Therapeutics, Inc.
New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous...